Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006108 · ClinicalTrials.gov registry record · Phase 1
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006108: Completed Phase 1 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT00006108 is a Phase 1 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006108, a Phase 1 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining capecitabine, paclitaxel, and trastuzumab in treating patients who have metastatic breast cancer.
Interventions
- DRUG paclitaxel
- DRUG capecitabine
- BIOLOGICAL trastuzumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2002-07 |
| Phase | Phase 1 |
What the finished NCT00006108 record still lists
NCT00006108 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00006108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006108 about?
NCT00006108 is a clinical study titled "Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemothera...
What is the current status of trial NCT00006108?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00006108?
The interventions under investigation include: paclitaxel (DRUG), capecitabine (DRUG), trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006108?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia